Ipsen (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average – Should You Sell?

Ipsen S.A. (OTCMKTS:IPSEY)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $29.66 and traded as high as $30.47. Ipsen shares last traded at $30.47, with a volume of 548 shares trading hands.

Analysts Set New Price Targets

Separately, Royal Bank of Canada upgraded shares of Ipsen from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 16th.

Ipsen Stock Performance

The company has a 50-day simple moving average of $29.03 and a 200-day simple moving average of $29.66.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.